The chloracetanilide herbicide alachlor (2-chloro-2',6-diethyl-N -(methoxymethyl)-acetanilide) induces nasal neoplasms in rats following chronic dietary exposure. The present study sought to identify the cellular origin and mechanisms of tumor induction and progression. Male Long-Evans rats were fed alachlor (0 or 126 mg/kg/day) beginning at 6 weeks of age. Following 1 month of alachlor ingestion, neither histological abnormalities nor enhanced cell division (assessed by BrdU incorporation) occurred in any region of the nasal cavity. Six months of alachlor exposure resulted in proliferation of basal and nonbasal cells in the olfactory mucosa while inducing nasal masses in 7 of 15 animals. Tumors ranged from dysplastic plaques to polypoid adenomas and originated in the olfactory regions of the nasal cavity. Neoplasms were associated with regions of respiratory metaplasia and were often covered with a low cuboidal, poorly ciliated epithelium. Tumor cells did not express characteristics of the olfactory mucosa, including olfactory marker protein (OMP, for neurons) and NMa (antibody recognizing cytochrome P450 [CYP] 2A3, found in Bowman's glands). Sites of plaque and tumor development coincided with regions of NMa immunoreactivity. These data suggest that local metabolism is important in alachlor-induced olfactory tumors and support the concept that metaplastic respiratory epithelial cells give rise to the observed neoplasms.
INTRODUCTION
Alachlor (2-chloro-2',6-diethyl-N-(methoxymethyl)acetanilide) is a pre-and early postemergent herbicide used principally in the production of corn, peanuts, and soybeans (22) . In several chronic feeding studies, alachlor has been demonstrated to be a nasal carcinogen in rats at dietary equivalent doses ranging from 2.5-126 mg/kg/ day (44) . The incidence of neoplasms is dose dependent.
While alachlor-induced nasal masses have been described as adenomas and adenocarcinomas (44) , a reassessment of their morphologic features has suggested that the tumors arise in the olfactory mucosa (35) . The potential for human exposure is significant, given that chloracetanilides are widespread drinking water contaminants, albeit generally at low levels (27, 44) , and new members of this class of pesticide have recently been registered for use (45) . Because of the potential for ground water contamination, alachlor is designated a restricted use pesticide (45) . The US EPA classified alachlor as a class B2, or probable, carcinogen in humans (44) , with more recent recognition that this risk is likely limited to very high exposures (45) .
Exposure of rats to alachlor for 6 months followed by an alachlor-free holding period was reported to be sufficient to induce nasal tumors late in life, suggesting that alachlor-induced damage represents an irreversible initiating event (44) . Alachlor has been demonstrated to have mutagenic activity in Salmonella typhimurium TA100 and in the mouse lymphoma assay in the presence of an activating system (S9 fraction) derived from olfactory mucosa (47) . The mouse lymphoma results revealed evidence of both point mutations and clastogenicity (47) . Alachlor has been shown to cause single strand breaks in freshly isolated rat hepatocytes (3) and is clastogenic in both Chinese hamster ovary (CHO) cells and human lymphocytes (9, 17, 29, 32, (40) (41) (42) . This laboratory (47) , as well as others (45) , has demonstrated that alachlor is not mutagenic in the presence of activating systems prepared from nontarget tissues, including nasal respiratory mucosa and liver. Taken together, these data strongly suggest that alachlor carcinogenicity is dependent on bioactivation to 1 or more mutagenic metabolites (8) and that one of the target tissues for alachlor-induced carcinogenicity, the olfactory mucosa, is capable of participating in alachlor metabolism. However, specific mechanisms respon-sible for the induction of nasal tumors have not been investigated.
The present experiments were performed as part of a larger effort to identify the cellular origin of and the mechanisms underlying alachlor-induced nasal tumors in rats. We now report results for the 1-month and 6-month interim time points of an ongoing chronic feeding study. Our findings provide substantial evidence to support region-specific metabolism and tissue susceptibility in the evolution of alachlor-induced nasal neoplasms.
MATERIALS AND METHODS
Study Design. The current study was designed as a 2year chronic feeding experiment with interim assessments at 1 month, 6 months, 1 year, and 18 months. This paper describes results determined at the 1-and 6-month time points. The test species, gender, age, study duration, route, and dietary equivalent dose of alachlor were selected to recapitulate parameters used in a prior chronic experiment that demonstrated the nasal carcinogenicity of this herbicide without an increase in mortality (44) . This work was conducted in accordance with federal animal care guidelines and was preapproved by the University of Cincinnati Institutional Animal Care and Use Committee.
Animals. Five-week-old male Long-Evans rats (n = 130) were obtained (Harlan, Indianapolis, IN) and acclimated to the housing conditions and feed for 1 week prior to inception of the feed study. During this week, animals were randomly assigned to treatment groups using a random number-generating program (Sharp Model EL-9300C calculator, Mahwah, NJ), and baseline body weights were recorded for each rat. Rats were housed individually in 18.5 X 9.5 X 6.5-inch cages containing sterilized corn cob bedding (Anderson's Bedding, Maumee, OH). Control and alachlor-treated rats were housed in the same room and were randomly dispersed among the racks. Cages were rotated to new positions on the rack twice per month, and racks were moved once weekly in order to maximally randomize housing conditions. Rats received alachlor at a dietary equivalent dose of either 0 or 126 mg/kg/day mixed into LM-485 sterilizable mouse/rat powdered diet (Harlan/Teklad, Indianapolis, IN). The amount of alachlor required to achieve the target dose was calculated based on total body weight and 24hour food consumption data that were measured weekly in 5 randomly selected control and 10 randomly selected alachlor-treated rats. Food was administered in glass cups fitted with stainless-steel screw caps. Cages and feeding cups were sanitized weekly. The environment was maintained at 22 ± 1°C, with a relative humidity of 50% ± 10%. Lighting was maintained on a 12-hour dark/12-hour light cycle, and animals were allowed tap water ad libitum.
Chemicals. Alachlor (98-99+% pure) was obtained from Chem Service (West Chester, PA) and stored, desiccated, at -20°C until use. All chemicals used for tissue embedding, histology, and immunohistochemistry were of the highest available commercial grade. Bromodeoxyuridine (BrdU) was acquired from Sigma (St. Louis, MO). A mouse monoclonal antibody directed against BrdU (catalog no. MAB 1467) was procured from Chemicon International (Temecula, CA). Goat antiserum raised against olfactory marker protein was the gift of Dr Frank Margolis (University of Maryland). Dr Xinxin Ding (Wadsworth Center, New York State Department of Health, Albany, NY) provided the rabbit polyclonal anti-NMa antibody [which was originally raised against rabbit cytochromes P450 [CYPs] 2A10/11 but also recognizes CYP2A3 in the rat (30) ]. Primary monoclonal anti-p53 antibody (NCL-p53-CM 1 ) was purchased from Vector Labs (Burlingame, CA). Polyclonal goat antirat CYP3A2 antiserum, which, according to the manufacturer, also recognizes rat CYP3A1, was obtained from Gentest (Wobum, MA). Dr Sarah K. Pixley (University of Cincinnati, Department of Anatomy and Cell Biology) provided aliquots of primary monoclonal antibody directed against SUS1, a marker of sustentacular cells (23) , and 2H4, a marker of secretory respiratory epithelial cells (38) . Biotinylated secondary antibodies and indirect immunoperoxidase detection kits based on the avidin-biotin complex method (Vectastain Elite and Vector DAB substrate kits) were obtained from Vector Labs and reconstituted according to the manufacturer's instructions.
Histopathology. Two hours prior to necropsy, each rat received an intraperitoneal BrdU injection (100 mg/kg) in warm physiological saline. Rats were killed using carbon dioxide and then decapitated. Nasal cavities were flushed with neutral buffered 10% formalin and then postfixed for 48 hours by immersion in the same solution. Samples were then decalcified for 7 days by immersion, with constant stirring, in 10 L of 10% formic acid containing Rexyn ion exchange resin (Fisher, Pittsburgh, PA). The decalcified tissues were washed overnight in cold running tap water, trimmed transversely according to a standard protocol (49) , and embedded in paraffin. Serial 5-)JLm-thick sections were cut and mounted on ProbeOn slides (Fisher Scientific, Pittsburgh, PA). Nasal lesions were evaluated at 2 levels in the ethmoid turbinate region of the nasal cavity (33) . These levels were delineated using previously described morphological criteria; 1 section (rostral) corresponded to approximately level 23, and the other section (caudal) corresponded to approximately level 26 (33) . One section was stained with hematoxylin and eosin (H&E) for conventional morphologic assessment. Lesions were scored using standard histopathologic criteria (Table 1 ). Periodic acid-Schiff (PAS) staining (6) was performed on serial sections of blocks that, on microscopic evaluation, were found to contain neoplasms.
Immunohistochemistry. Serial sections were used to examine selected cell type-and function-specific markers. A series of proteins were assessed (Table 2) after 6 months of alachlor exposure, while only BrdU immunohistochemistry was performed on tissues collected at the 1-month time point. All sections contained positive (eg, olfactory mucosa) and negative control tissues. In general, sections were deparaffinized, rehydrated, and digested in 0.01 % proteinase K (type XXVIII from Tritirachium album; Sigma) for 5 minutes to degrade proteinaldehyde cross links. Next, sections were rinsed in phosphate buffered saline (PBS) and blocked using 10% horse serum for 20 minutes. The primary antibody, diluted in 10% serum, was applied for 90 minutes at room temperature (RT) in a humidified chamber. Next, the sections were sequentially incubated at RT in solutions containing biotinylated secondary antibody (Vectastain kit, Vector Labs; 45 minutes), ABC reagent (45 minutes), and chromatic reagent (a mixture of diaminobenzidine HCI, hydrogen peroxide, and nickel; 1 minute). All steps following the primary antibody incubation were separated by triplicate PBS rinses. Finally, slides were rinsed in water, counterstained with hematoxylin or eosin (or both), dehydrated, and cover-slipped with a permanent mounting medium. Three slight variations from this standard protocol were employed. For BrdU immunohistochemistry, sections were incubated in 1 N HCI for 1 hour to denature DNA prior to the blocking step. For SUS 1 and 2H4, the protease digestion step was increased (0.05% solution for 20 minutes). For p53, FAT7 cells (2), grown under aseptic conditions on ProbeOn slides (Fisher), were used as a positive control &dquo;tissue.&dquo; This control was essential because any noninvasive nasal lesions induced by 6 months of alachlor ingestion might not have expressed p53. This absence had been observed previously in normal mucosa as well as benign and premalignant nasal lesions in humans (10) . Cell Proliferation. Olfactory epithelial proliferation was quantified by counting BrdU-positive (ie, S-phase) basal cell nuclei, including both so-called horizontal and globose basal cells (19, 43) , for a given length of olfactory mucosa. These lengths were determined by planimetric analysis of the mucosal basement membrane in low-power photomicrographs. The unit length labeling index (ULLI) was defined as the number of S-phase cells per millimeter of basement membrane (34) . ULLIs were calculated for 8 regions of the nasal cavity (similar to a previously described strategy (47) , as well as for the entire level III nasal cavity section. Conventional nomenclature (49) for ectoturbinates (1', 2') and endoturbinates (1-3) was employed. In a few caudal sections, olfactory mucosa was also present on endoturbinate 4, a small scroll located ventral to endoturbinate 3.
Western Blot Analysis. The CYP3A content of control rat olfactory mucosa was compared to liver by western blot analysis of the respective tissue S9 preparations. Briefly, liver S9 was prepared by mincing liver in icecold potassium buffer (50 mM with 0.1 mM EDTA and 1.15% KCI) followed by homogenization with a ground glass homogenizer on ice; olfactory mucosal S9 was similarly prepared from the ethmoid turbinates and caudal one-third of the nasal septum. Homogenates were centrifuged at 9,000 X g (4°C) to remove nuclei, and the resulting S9 fraction was stored at -80°C until use. Protein concentrations were determined using the BioRad protein reagent (BioRad, Hercules, CA). Proteins (5 pLgflane) were separated on 10% polyacrylamide minigels and transferred to nitrocellulose (BioRad). After staining with Ponceau red to confirm equivalent loading across lanes, membranes were blocked with 3% bovine serum albumin in PBST (0.01 M phosphate buffered saline containing 0.1 % Tween 20). Membranes were then incubated in primary antibody (antirat CYP3A2, 1:500 dilution in PBST) for 90 minutes at RT. After triplicate washes in PBST, the membrane was incubated in horseradish peroxidase (HRP) conjugated antigoat IgG secondary antibody (Dako, Carpinteria, CA; 1:1000) for 45 minutes at RT. After triplicate washes, protein bands were visualized using enhanced chemiluminescence (ECL, Amersham, Arlington Heights, IL) with exposure to x-ray film (Kodak). Data Analysis. Cell turnover between control and treatment groups was compared by constructing a mean vector for each cohort at each time point and then evaluating the equivalency of these values using a multivariate analysis of variance (MANOVA) test (26) . A given vector had 8 components, each representing a regional ULLI (calculated as described previously). Potential correlations between vector components were considered.
Formal assumptions of equality of the variance-covariance matrices for the, 2 groups and univariate normality of the data by region of the nasal cavity were examined. A discriminant function was calculated (39) , and individual t-tests with a Bonferroni correction were performed. The nominal p-value for significance was taken to be 0.007, thus controlling for the experiment-wise error rate to about 0.05. Comparisons with p-values between 0.01 TABLE 2.-Nasal mucosal-and cancer-associated antigens assessed using immunohistochemistry. and 0.007 were considered to be approaching significance. These analyses were performed for ULLIs acquired for S-phase (BrdU-labeled) cells in both basal and nonbasal populations.
RESULTS

One-Month Time Point
Control and alachlor-treated rats (n = 10/group) were examined after 1 month of alachlor administration.
Body Weights and Overall Animal Health. The total body weights of alachlor-treated rats were not reduced relative to those of the untreated controls (Figure 1 ).
Alachlor administration was not associated with changes in the appearance or behavior (eg, grooming) of the alachlor-exposed rats.
Histopathology. Examination of H&E-stained nasal cross sections revealed no alachlor-induced microscopic lesions in the olfactory mucosa, indicating no evidence of cytotoxicity or other histological alterations in the target tissue.
Cell Proliferation. As shown in Figure 2a , cell turnover (measured by counting BrdU-labeled nuclei) was not altered following 1 month of alachlor administration. This finding held true for ULLI obtained for the mucosa as a whole, for various anatomic locations, and for specific cell populations of the olfactory mucosa (eg, epithelial basal cells). Similarly, the ULLI of nonbasal cells in the mucosa was not increased (Figure 2b ). Few cells in the subepithelial compartment (eg, Bowman's glands) incorporated BrdU, so counts in this region of the olfactory mucosa were not collected.
Six-Month Time Point
Five control and 15 alachlor-treated rats were evaluated after 6 months of alachlor administration.
Body Weights and Overall Animal Health. The total body weights of rats ingesting alachlor were not reduced relative to those of the untreated controls (Figure 1 ). Alachlor administration was not associated with changes in the appearance or behavior (eg, grooming) of the alachlor-exposed rats.
Histopathology. Evaluation of H&E-stained sections revealed 1 or more masses arising from the nasal mucosa in 7 of 15 alachlor-treated rats ( Table 3 ). Five of these animals had neoplastic lesions, including raised plaques (2 rats) and/or elevated polyps (5 rats). Plaques ( Figure  3 ) consisted of small, flat nodules covered by columnar to pseudo-stratified, poorly ciliated respiratory epithelium. Polyps (Figure 4 ) exhibited a similar composition but were characterized by an elevated (space-occupying) mass supported by a narrow stalk. Tortuous glands penetrated the fibrovascular core of both preneoplastic lesions. Mitotic figures were relatively rare. Three alachlortreated rats had neoplasms that had characteristics of well-differentiated polypoid adenomas (Figure 5a ). These benign neoplasms were large space-occupying masses characterized by a lining of poorly ciliated, simple columnar epithelium, numerous tortuous glands, and modest numbers of mitotic figures. In 1 rat, cytological characteristics of 1 dysplastic adenoma were pleomorphic (Figure 5b ), suggesting the onset of anaplasia and incipient development of an invasive malignancy. These nasal masses originated in specific domains of the ethmotur- (Figure 7 ). However, their stalks appeared to erupt from regions of markedly disorganized epithelium or respiratory metaplasia rather than from intact olfactory mucosa, which is the normal lining of the ethmoturbinates. Control rats did not display similar metaplastic or neoplastic lesions. In PAS-processed sections, positive staining was observed in goblet cells of the respiratory mucosa, in Bowman's glands of the olfactory mucosa, and in the contents of the lumens of many of the tortuous glands in the tumors. Most neoplastic cells, however, did not stain with PAS.
Immunohistochemistry. Tumor cells did not express immunohistochemical markers characteristic of the olfactory mucosa, including olfactory marker protein (OMP, for mature sensory neurons) and NMa (for CPY2A3). The staining pattern for the SUS 1 antibody did not correspond to the known distribution of sustentacular cells, likely as a consequence of the processing methods [ie, TABLE 3 .-Occurrence and histopathological features of nasal lesions following 6 months of alachlor ingestion.a a a Data acquired from 7 affected animals in the alachlor-treated cohort. Abbreviations: R = rostral, C = caudal (corresponding to planes 23 and 26, respectively, previously defined in the rat nose (33) ). the original protocol for this antibody did not employ decalcification or paraffin embedding (23) ]. While FAT-7 cells were strongly positive for an antibody recognizing both native and &dquo;mutant&dquo; p53 protein, neither the tumors nor the plaques were labeled. As predicted, the 2H4 antibody displayed strong immunoreactivity with the respiratory mucosa of the nasopharynx and ventral-lateral wall of the nasal cavity. In contrast, alachlor-induced neoplasms were in general negative for this antigen, although 1 rat exhibited immunoreactivity in a focus of respiratory metaplasia on the 1' ectoturbinate ( Figure 6 ).
The distribution of NMa immunoreactivity in specific regions of the nasal cavity in all sections stained with this antibody. Staining was observed in lateral and ventral quadrants of the nasal cavity but not in the mucosa lining the dorsal medial meatus and the dorsal septum ( Figure  7 ). Anti-NMa immunoreactivity was localized primarily to the Bowman's glands and, to a lesser extent, in the neuroepithelium itself of the ventral and lateral airways. The mucosal staining appeared to represent ducts of Bowman's gland. Cell Proliferation. Evaluation of the slides stained with an antibody to BrdU revealed an overall trend toward enhanced basal cell proliferation in alachlor-treated rats compared to the age-matched controls (Figure 8a ). Basal cells represent the population of cells that normally divides in the olfactory mucosa. Statistical significance (p < 0.007) was attained for the 1' ectoturbinate and the 1 and 3 endoturbinates, all of which have been sites of tumor formation in slides evaluated to date.
In the course of counting the BrdU-positive basal cells, a striking number of labeled cells were noted at all levels of the olfactory epithelium (ie, in nonbasal locations). Statistical significance was attained in all regions except for the dorsal medial meatus and the 4 endoturbinate (Figures 8b and 9 ).
Furthermore, in analyzing the data, it appeared that alachlor-treated rats bearing neoplasms had higher levels of proliferation than did non-tumor-bearing alachlor-treated rats. Therefore, we also expressed the data in terms of alachlor-treated animals with and without neoplasms vs controls (Figure 8c, d) . Despite the overall trend in the data, the ULLI between alachlor-treated rats with tumors and alachlor-treated rats with no tumors was significantly different only on the 2' endoturbinate ( Figure   8d ). Western Blot Analysis. As shown in Figure 10 , a robust band with a molecular weight of approximately 56 kD was present only in liver S9 preparations on western blots with an antibody recognizing rat CYPs 3Al/2; the corresponding band was not present in olfactory mucosa S9. The blot was subsequently stripped and reprobed with the NMa antibody described previously, and CYPs immunoreactive with the olfactory mucosal S9 fraction were detectable with this antibody (data not shown).
DISCUSSION
In the current study, alachlor-treated rats developed preneoplastic and neoplastic lesions following 6 months of alachlor exposure. The histologic appearance of the largest masses was consistent with previous descriptions of polypoid adenomas in the nasal cavity (1, 4, 12) . Further, the fact that the glandular contents of the tumors were consistently PAS positive strengthened this diagnosis (4). These morphologic changes occurred specifically in the ventral and lateral regions of the posterior nasal cavity. Other chloracetanilides, namely acetochlor and butachlor, have been shown to share this pattern of lesion distribution (35) . The range and number of lesions suggested that an orderly evolution takes place, with regions of altered epithelial differentiation giving rise to FIGURE 6.-Respiratory metaplasia associated with the development of alachlor-induced tumors was generally not accompanied by expression of the secretory granule antigen 2H4. a) Polypoid adenoma arising on the medial aspect of the endoturbinate 2. The epithelium immediately adjacent to the tumor has undergone respiratory-like metaplasia (arrowheads), and the surface of the tumor is similarly covered by a low cuboidal ciliated respiratory-like epithelium. The opposite face of the turbinate is covered by the normally occurring respiratory epithelium. H&E, bar = 20 pLm. (b) Serial section of (a) stained with 2H4 antibody, showing normal olfactory-respiratory junctions (*) and 2H4 immunoreactivity in the normally occurring respiratory mucosa (arrows) but not in the metaplastic epithelium lining or adjacent to the tumor (arrowheads). 2H4/eosin, bar = 20 ~Lm. (c) Focus of respiratory metaplasia on the 1' ectoturbinate of an alachlor-treated rat (arrowheads). H&E, bar = olfactory epithelial cells as measured by BrdU incorporation into S-phase nuclei was increased by 6 months of alachlor ingestion. A comparison of alachlor-treated rats without vs with tumors revealed trends toward increased proliferation in basal cells (c) and nonbasal cells (d) of tumor-bearing animals. * denotes statistically significant differences from controls, p < 0.05; ** denotes statistically significant difference from alachlor-treated rats without tumors. Abbreviations are identical to those in Figure 2 . small raised plaques, which progress to elevated neoplastic polyps, and finally progress to well-differentiated adenomas. Given the apparent evolution of the lesions and the multiplicity of masses, it seems likely that alachlor exposure for periods longer than 6 months will result in further progression of well-differentiated benign tumors to anaplastic adenomas and even adenocarcinomas (Preliminary assessment of 2 rats exposed to an alachlorcontaining diet for 10.5 months and 11 months, respectively, revealed the existence of multiple adenomas and an adenocarcinoma). The early alachlor-induced lesions are morphologically quite distinct from the esthesioneuroepitheliomas that form as a result of exposure to Nnitrosopiperidine and 2,6-dimethylnitrosomorpholine (46) but are very similar to a population of tumors resulting from NNK exposure (1) .
The early occurrence of definitive neoplasms over the time course of the current study was unexpected. A prior report describing an alachlor feeding study in rodents that used the same dietary equivalent dose suggested that her-bicide exposure for at least a year was required to induce nasal tumors (44) . However, our data show that preneoplastic lesions and frank neoplasms can develop in the nasal cavity after only 6 months of dietary exposure to this agent. This result has important implications with respect to interpreting the outcome of the previously reported 6-month &dquo;stop study&dquo; (44) . Our initial interpretation of the prior findings (44) was that alachlor exposure for 6 months had induced sufficient genotoxic damage to initiate tumor formation and that the tumors developed during the subsequent alachlor-free holding period. Instead, the present data indicate that the alachlorexposed rats likely had a wide range of rapidly evolving preneoplastic lesions and benign neoplasms by the time that the alachlor treatments ceased. Therefore, it is clear that the event(s) predisposing the tissue to carcinogenesis occurs earlier than previously suspected.
The morphologic lesions induced in the nasal cavity by chronic ingestion of alachlor were associated with marked increases in nasal cell turnover, a finding widely FIGURE 9.-Morphologic comparison of proliferating olfactory epithelial cells in alachlor-treated (a) and control (b) rats. Abnormal features in alachlor-treated animals included basal cells (*) with transmucosal apical extensions (arrowheads) and/or rounded profiles and proliferating nonbasal cells (arrows). In control rats, BrdU is incorporated only into horizontal (arrowheads) and globose (arrows) basal cells. Indirect immunoperoxidase method to detect BrdU, with hematoxylin. X200. regarded to precede the evolution of neoplasms (7) . Relative to control rats, alachlor-exposed animals contained many more proliferating basal cells in most nasal regions. In addition, a striking feature of the present study was the marked increase in numbers of S-phase nonbasal cells in the olfactory mucosa of alachlor-treated rats; in control rats, BrdU is rarely incorporated in olfactory mucosal cells other than basal cells. Our study did not include cell proliferation assessments between the 1-and 6-month time points, so our data cannot be used to predict when, during the progression of these early lesions, the rate of mucosal cell proliferation first becomes elevated. In addition, Figures 8c and d show a trend toward a difference in proliferation response between tumor-bearing and tumor-free alachlor-treated rats; it is attractive to speculate that this response may have reached statistical significance if the number of tumor-bearing rats analyzed had been greater. Obviously, additional time-course experiments to establish the onset of enhanced nasal cell proliferation in relation to the development of early mucosal lesions will be required. Such data may then be used to refine the risk of alachlor-induced carcinogenicity in humans.
The widespread nature of the proliferative response in the olfactory mucosa, as well as the altered pattern of proliferation, prevented a definitive assignment of specific cell(s) as the target for the genetic alterations that led to carcinogenicity. This issue was further complicated by the technical difficulties associated with performing immunohistochemical studies on nasal cavity sections that have been fixed in neutral-buffered formalin, decalcified in formic acid, and embedded in paraffin. Although this fixation/decalcification protocol was considered standard (49) , it is clear that it does not work for every antibody. Cryostat sectioning of tissues fixed in 4% para- formaldehyde or fixation with 1 % periodate-lysine-paraformaldehyde followed by decalcification in saturated EDTA is necessary for detection of some olfactory mucosal antigens (23, 24, 38) .
In the current study, a high percentage of alachlor-induced neoplasms were associated with foci of respiratory-like metaplasia. In contrast to other olfactory mucosal toxicants associated with respiratory-like metaplasia [several are described in (20) ], alachlor-induced epithelial changes occurred in the absence of an initial cytotoxic injury. Although other reports have described an association between chemically induced neoplasms of the olfactory mucosa and squamous or respiratory metaplasia (4) , there are notable exceptions where respiratory metaplasia of the olfactory mucosa is not accompanied by chemically induced proliferative lesions (20, 36) . The metaplastic epithelium adjacent to and/or associated with alachlor-induced tumors was generally negative for 2H4, although 1 positive focus was found (Figure 6 ), suggesting that overall the new respiratory epithelium is relatively undifferentiated. A progression from olfactory mucosa to respiratory metaplasia was also noted with the development of olfactory mucosal tumors, including polypoid adenomas, in response to subchronic exposure to NNK (1). In addition, several alachlor-induced tumors appeared to arise at the junction of the olfactory and respiratory mucosa in the dorsal-lateral nasal cavity. This junctional region appears to have 1 or more as yet undetermined factors that predispose it to toxic insult, as indicated by our previous identification of this site as being extremely sensitive to acetaminophen-induced degeneration (15) . Based on observations made in this study to date, it appears that alachlor alters the normal pattern of proliferation and differentiation in the olfactory mucosa, as the metaplastic and neoplastic changes occur in the absence of frank cytotoxicity. We are currently working to better define the specific induction and progression events as well as the timing of these changes.
The NMa immunohistochemistry data presented here, together with previous work (5, 35, 47) , strongly suggest that alachlor-induced genotoxicity and carcinogenesis in the nasal mucosa result from local bioactivation of an alachlor metabolite generated in the liver. This hypothesis was supported by the demonstration that proliferative lesions and NMa expression [which corresponds to CYP2A3 in rat olfactory mucosa (30) ] are colocalized to the ventral and lateral quadrants of the nasal cavity. Other chloracetanilide herbicides, acetochlor and butachlor, also induce nasal tumors with a comparable pattern of regional distribution (35) . Further support for a role for olfactory mucosal enzymes in chloracetanilide bioactivation is provided by the previous observation that alachlor is not mutagenic in the absence of an olfactory mucosal bioactivating system (46) . The NMa localization data that we present here would have, in retrospect, altered our approach to preparing the olfactory mucosal S9 activating system for the in vitro mutagenesis assays. We had set out to test the hypothesis that 1 or more enzymes present in the olfactory mucosa, but not the liver, were responsible for bioactivation of alachlor to a mutagen (47) . Given that the present results (Figure 7) show that the mucosa of the nasal septum and dorsal medial meatus is largely void of NMa immunoreactivity, this portion of the olfactory mucosa would have been avoided in preparing the S9s for in vitro mutagenesis analyses for the purposes of testing this hypothesis.
The present studies also provide further support for hepatic metabolism of alachlor in the bioactivation sequence. CYP3A4, the predominant oxidative enzyme in human liver (28), appears to be responsible for the initial steps of alachlor metabolism to 2,6-diethylaniline (5) . While no data have been reported to show that 1 or more rat CYPs 3A have the analogous activity toward alachlor, there is certainly substantial data supporting the idea that rat and human CYPs 3A share significant similarities in their profiles of substrate specificities and kinetics (13, 18, 31 ) . We have previously demonstrated that at least 1 CYP3A isoform is also present in mouse olfactory mucosa (15) . However, the present data demonstrate that CYPs 3A1/2 are not detectable, either by western blot (Figure 10 ) or by immunohistochemistry (data not shown), in the male Long-Evans rat olfactory mucosa. Therefore, it seems likely that intermediate metabolites of alachlor are formed initially in an extranasal tissue and subsequently transported to the olfactory mucosa. Further support for this possibility rests in the observation that 2,6-diethylaniline, which is believed to be a pivotal metabolite of alachlor (11) , can be detected in the blood following IP injection of alachlor (14) . Therefore, the present data provide substantial support for delivery of an intermediate alachlor metabolite to the nasal mucosa via the bloodstream, with subsequent bioactivation in the nasal mucosa. This sequence of metabolic events is comparable to that noted for lidocaine. A principal metabolite of lidocaine that is produced in human liver is 2,6-dimethylaniline (2,6-xylidide); this compound similarly acts as a rat nasal carcinogen (21, 37) . Additional work will be needed to elucidate the precise roles of locally produced vs systemically delivered alachlor metabolites in the initiation of neoplastic nasal lesions.
In summary, our present data have substantially expanded our understanding of alachlor-induced nasal carcinogenesis. We have provided substantial evidence in support of a sequential evolution of neoplastic lesions, beginning with altered patterns of olfactory mucosal differentiation and cell proliferation. Furthermore, we have shown that local bioactivation of intermediate alachlor metabolites is almost certainly a requirement for the development of neoplasms. These data, coupled with future dose-response evaluations of the significant endpoints of the present study, should prove helpful in refining risk assessments for human populations exposed to high occupational or low environmental levels of this and other chloracetanilide compounds.
